Thursday, March 28, 2024 9:51:54 PM
You fail to realize that in 2020, there were like a 1/2 billion fewer shares! Hello dilution gets factored in, duhhh
Plus, that was when hope was still alive, new shares being issued like candy , pump and dumps, hopes and dreams. Now, the FDA is OUT, the EU is OUT, Canada Health is OUT, there's only the measly MHRA with the tiniest of markets, and even they will likely NOT approve DCVAX for marketing. ( My opinion)
The spoofing case is all over, but the crying... and even if there was a tiny MHRA limited approval, Advent books all the revenues, bears all the costs and gives NWBO a small royalty ( after costs) - not nearly enough to justify a $600 + Million market cap! This stock is already 10X overvalued based on any potential UK royalties, IMHO....
Technical analysis involves a lot more than drawing imaginary lines with a crayon. And past PPS when the outstanding shares were half of what they are now has to be accounted for as well. Dilution is a real thing newbie!
You literally know nothing and shouldn't be posting charts to influence potential buyers.
What do you think is the total potential revenue for NWBO in the event of an ( unlikely) MHRA approval? Do you even have an idea? How many patients will there be, will UK pay $150K for them, how much trickles down to NWBO in net royalties if they even do pay?
What is the NWBO shareholder's interest in Advent? If any?
What other DC vaccines are the competition?
Why did the FDA pass?
Why did EU pass?
Why did Canada pass?
Did you know that DCVAX has been available via C Care in Europe since 2014 and has been FREE for German citizens? No one wants it....
Do past prices and chart patterns change when the shares have been diluted by more than half?
Short sellers and institutions have long since abandoned this stock. It's just ignorant retail buyers and Linda Powers selling to them on an almost daily basis, that's it... NO SHORTS, and NO institutional buyers... just the company selling shares to retail while trying to keep the lights on and salaries continuing...
Plus, that was when hope was still alive, new shares being issued like candy , pump and dumps, hopes and dreams. Now, the FDA is OUT, the EU is OUT, Canada Health is OUT, there's only the measly MHRA with the tiniest of markets, and even they will likely NOT approve DCVAX for marketing. ( My opinion)
The spoofing case is all over, but the crying... and even if there was a tiny MHRA limited approval, Advent books all the revenues, bears all the costs and gives NWBO a small royalty ( after costs) - not nearly enough to justify a $600 + Million market cap! This stock is already 10X overvalued based on any potential UK royalties, IMHO....
Technical analysis involves a lot more than drawing imaginary lines with a crayon. And past PPS when the outstanding shares were half of what they are now has to be accounted for as well. Dilution is a real thing newbie!
You literally know nothing and shouldn't be posting charts to influence potential buyers.
What do you think is the total potential revenue for NWBO in the event of an ( unlikely) MHRA approval? Do you even have an idea? How many patients will there be, will UK pay $150K for them, how much trickles down to NWBO in net royalties if they even do pay?
What is the NWBO shareholder's interest in Advent? If any?
What other DC vaccines are the competition?
Why did the FDA pass?
Why did EU pass?
Why did Canada pass?
Did you know that DCVAX has been available via C Care in Europe since 2014 and has been FREE for German citizens? No one wants it....
Do past prices and chart patterns change when the shares have been diluted by more than half?
Short sellers and institutions have long since abandoned this stock. It's just ignorant retail buyers and Linda Powers selling to them on an almost daily basis, that's it... NO SHORTS, and NO institutional buyers... just the company selling shares to retail while trying to keep the lights on and salaries continuing...
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
